The relevance of IL-33/ST2 signaling as a regulator of Treg populations has been documented in both steady-state conditions and various diseases, including gastrointestinal disease, lung disease, cancer, multiple sclerosis, and other autoimmune models (53). This evidence concerns the gene IL1RL1 and multiple sclerosis.